Upstream Bio
Agent39Agent Readiness: 39/100. Below median. Measured by StartupHub.ai. Median 41.Trust83Data Trust: 83/100. Top 25%. Measured by StartupHub.ai. Median 61.Clinical-stage biotech developing a monoclonal antibody targeting TSLP for inflammatory diseases.
About
Upstream Bio is a clinical-stage biotechnology company focused on developing novel therapies for inflammatory diseases. Their lead program is a monoclonal antibody designed to inhibit the TSLP receptor, a key upstream mediator in multiple inflammatory signaling pathways. By targeting TSLP, Upstream Bio aims to address a broad range of immune-mediated conditions.
Key facts
At-a-glance profile data
- Website
- upstreambio.com
- Headquarters
- Waltham, United States
- Founded
- 2021
- Employees
- 75
- Total funding
- $400M (Series B)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 8 Jun 2023 | Series B | $200M | Enavate Sciences, Venrock Healthcare Capital Partners |
| 2 Jun 2022 | Series A | $200M | OrbiMed, Maruho Co |
Tech stack
Detected on upstreambio.com, last scanned 20 Oct 2026. Run your own scan
- Frontend
- jQuery, Bootstrap
- Analytics
- Google Tag Manager
- SEO
- Yoast SEO
- CMS / Builders
- WordPress
- CDN
- Cloudflare
- Email provider
- Microsoft 365
Frequently asked
Is Upstream Bio trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Upstream Bio is 83 out of 100, a trusted rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has Upstream Bio raised?
Upstream Bio has raised a total of $400M in funding. The most recent round on record is Series B.
How many employees does Upstream Bio have?
Upstream Bio has approximately 75 people on record.
